（文章来源：证券日报） 证券日报网讯九安医疗8月21日在互动平台回答投资者提问时表示，二级市场股价的影响因素较多，短 期波动很难单纯的归因为公司基本面，投资者的认知差异和策略偏好也有不同，导致市场对公司价值的 理解也存在差异，但是，公司相信，从长期的视角来看，公司的基本面会反映出公司的价值，公司将持 续在业务层面发力，不断提升业务及大类资产配置带来的收益，从而提升公司价值。与此同时，公司非 常重视投资者关系，并持续积极地与金融机构及机构投资者保持交流，希望市场可以认同公司的价值， 并给予客观的估值。 ...

Group 1 - The company received an inquiry regarding its diabetes care business revenue for 2025 and its expected growth compared to 2024 [2] - The company reported that the total revenue from its diabetes care business for the year 2024 is projected to reach 76.16 million yuan [2] - The company indicated that details regarding the performance of the diabetes care business in the first half of 2025 will be available in its semi-annual report for that year [2]

Core Viewpoint - The company is actively advancing its "Internet + Healthcare" strategy, particularly focusing on the diabetes O+O model in both the US and China, with significant progress reported in patient management and revenue growth [1] Group 1: Business Development - The diabetes O+O model aims for full implementation in the US and China by the end of 2025, with ongoing expansion efforts [1] - As of the latest report, the model has been established in 50 cities across China and 394 hospitals, managing over 329,000 diabetes patients [1] - In the US, partnerships have been formed with approximately 74 clinics and 388 doctors, serving around 20,000 patients [1] Group 2: Performance Metrics - The management of diabetes patients has shown significant improvement, with the rate of achieving target HbA1c levels increasing from about 30% to 60% [1] - The adverse event rate has decreased to below 5%, and the standardized management rate has improved to 70% [1] - The company reported a revenue of 76.16 million yuan from diabetes care services in 2024 [1]

Company Overview - As of August 19, 2025, Jiuan Medical's stock price closed at 41.44 yuan, an increase of 0.84 yuan, representing a rise of 2.07% [1] - The company specializes in the research, production, and sales of medical devices, including home medical equipment such as blood pressure monitors and blood glucose meters [1] Market Performance - On August 19, the trading volume was 163,700 hands, with a transaction amount of 684 million yuan, and the stock experienced a fluctuation of 3.99% [1] - The net inflow of main funds on that day was 22.33 million yuan, accounting for 0.12% of the circulating market value [1] - However, over the past five trading days, there has been an overall net outflow of 24.52 million yuan, which is 0.13% of the circulating market value [1] Industry Context - Jiuan Medical operates within the medical device sector, which is characterized by the development and commercialization of various healthcare products [1]

Group 1 - On August 18, four companies announced stock repurchase progress, with two companies disclosing repurchase plans for the first time and two companies completing their repurchase plans [1] - Among the newly disclosed repurchase plans, one company announced a repurchase amount exceeding 10 million, with Honghui New Materials and Small Commodity City having the highest proposed repurchase amounts of 20 million and 193,500 respectively [1] - For completed repurchases, Shikong Technology and Tongcheng New Materials had the highest completed amounts, repurchasing 3.9488 million and 90,300 respectively [1] Group 2 - As of August 18, a total of 1,369 repurchase plans have been implemented this year, involving 1,077 companies, with 247 companies completing repurchases exceeding 100 million [1] - The companies with the highest repurchase amounts include COSCO Shipping Holdings, Tongwei Co., and Jiuan Medical, with completed repurchases of 2.146 billion, 2.008 billion, and 1.680 billion respectively [1]

资金流向方面，8月15日，九安医疗主力资金净流出10.67万元，近5日总体呈流出状态，5日共流出 1509.03万元。 天津九安医疗电子股份有限公司的主营业务是家用医疗器械的研发、生产及销售。公司的主要产品是 iHealth系列产品、非自主品牌产品、传统硬件产品、互联网医疗产品。 最新一期业绩显示，2025年一季报，公司实现营业收入5.07亿元，同比-33.49%；净利润2.66亿元，同比 7.62%，销售毛利率70.46%。 8月15日，九安医疗今日收盘40.42元，上涨1.58%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到11.36倍，创92天以来新低，总市值191.70亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均56.58倍，行业中值39.97倍，九安医疗排 名第32位。 序号股票简称PE(TTM)PE(静)市净率总市值(元)1九安医疗11.3611.490.89191.70亿行业平均 56.5852.305.00119.53亿行业中值39.9739.072.9157.03亿2英科医疗15.6416.861.39247.04亿3山东药玻 16.2816.331.871 ...

Core Viewpoint - The enthusiasm for share buybacks among listed companies has surged in 2023, with a significant increase in the number of buyback plans and the total amount allocated for these buybacks, reflecting a proactive approach to capital management and market confidence [1][2][3]. Group 1: Share Buyback Trends - As of March 16, 2023, 821 A-share companies have announced 830 buyback plans, with a total buyback limit exceeding 90 billion yuan [1]. - The number of companies engaging in "cancellation-type" buybacks has increased, with 57 new plans announced, indicating a focus on maintaining and enhancing stock prices [1][2]. - The total disclosed amount for buyback cancellations has reached 22.7 billion yuan, surpassing the total for the entire year of 2023 [2]. Group 2: Regulatory Support and Market Impact - The China Securities Regulatory Commission (CSRC) has expressed strong support for share buybacks, particularly cancellation-type buybacks, as a means to enhance shareholder returns and stabilize the market [2][3]. - New regulatory guidelines encourage companies to adopt buyback strategies, including the integration of buyback amounts into dividend payout calculations [2][3]. - The implementation of these guidelines is expected to lead to an increase in buyback frequency and amounts, thereby improving market confidence and stability [3]. Group 3: Leading Companies and Market Response - Major companies with market capitalizations exceeding 100 billion yuan, such as WuXi AppTec and Midea Group, are actively engaging in cancellation-type buybacks, setting a precedent for other firms [4][5]. - The announcement of substantial buyback plans has led to immediate positive stock price reactions, indicating investor approval and confidence in these strategies [5]. - The actions of leading companies are expected to have a demonstrative effect, encouraging other firms to adopt similar practices to enhance the overall investment environment [5].

Group 1 - The core viewpoint of the news is that Jiuan Medical's stock performance shows a significant decline in its price-to-earnings (PE) ratio, indicating potential undervaluation compared to the industry average [1] - As of August 11, Jiuan Medical's closing price was 40.12 yuan, with a PE ratio of 11.28, which is the lowest in 88 days, and a total market capitalization of 19.028 billion yuan [1] - The medical device industry has an average PE ratio of 56.56, with Jiuan Medical ranking 32nd among its peers [1] Group 2 - In terms of capital flow, Jiuan Medical experienced a net inflow of 28.665 million yuan on August 11, with a total inflow of 49.9093 million yuan over the past five days [1] - The company's main business includes the research, production, and sales of home medical devices, with key products being the iHealth series, non-self-branded products, traditional hardware products, and internet medical products [1] - The latest quarterly report for Q1 2025 shows Jiuan Medical achieved a revenue of 507 million yuan, a year-on-year decrease of 33.49%, while net profit was 266 million yuan, a year-on-year increase of 7.62%, with a gross margin of 70.46% [1]

来源：金融界 主力资金净流出居前的分别为安杰思（1536.17万元）、科华生物（1457.06万元）、海利生物（1440.72 万元）、华大基因（1419.47万元）、福瑞股份（1329.15万元）。 序号代码名称最新价涨跌幅主力净流入主力净占比1300760迈瑞医疗230.5-0.098724.29万元 6.07%2300753爱朋医疗34.261.935531.45万元7.53%3300314戴维医疗15.2510.035504.85万元 11.77%4603658安图生物42.343.394457.47万元15.08%5688273麦澜德44.759.234025.59万元9.14%6002432 九安医疗40.121.192866.50万元6.27%7600587新华医疗18.144.432682.44万元3.88%8300453三鑫医疗 9.413.982472.80万元10.27%9688271联影医疗130.68-0.021943.47万元5.25%10603309维力医疗 14.92.831756.01万元10.29% 8月11日，医疗器械行业上涨1.65%，今日主力资金流出4.97亿元，成分 ...

证券代码：002432 证券简称：九安医疗 公告编号：2025-054 天津九安医疗电子股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 天津九安医疗电子股份有限公司（以下简称"公司"）于2025年6月3日召开 第六届董事会第二十三次会议、第六届监事会第十八次会议，审议通过了《关于 拟注册和发行中期票据及超短期融资券的议案》。同意公司向中国银行间市场交 易商协会（以下简称"交易商协会"）申请注册发行总额不超过人民币35亿元（含 容详见2025年6月5日，公司于《证券时报》、巨潮资讯网（www.cninfo.com.cn） 披露的相关公告。 公司于近日分别收到交易商协会出具的《接受注册通知书》 （中市协注〔2025〕 MTN749号和中市协注〔2025〕SCP207号），交易商协会决定接受公司科技创新 债券注册。主要内容如下： 公司将严格按照有关法律法规、交易商协会相关自律管理规定及上述通知书 的要求，充分考虑公司资金需求和市场情况，在注册有效期内择机发行中期票据 和超短期融资券，并按照《非金融企业债务融资工具注册发行规则》《非金融企 业债务融资工具 ...